Pulse Biosciences, Inc. (PLSE) Stock

Pulse Biosciences, Inc. (PLSE) is a Healthcare stock trading at $47.91 (as of 2026-08-20), with a market capitalization of $3.42B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pulse Biosciences, Inc. develops bioelectric therapies using its Nano-Pulse Stimulation technology, delivered through its CellFX System. The company’s software-enabled platform delivers brief electrical pulses to targeted cells for the non-thermal treatment of medical conditions, aiming to spare surrounding non-cellular tissue for patients.

Understand Pulse Biosciences, Inc.: how it makes money

Pulse Biosciences develops and sells the CellFX System, a tunable, software-enabled platform using Nano-Pulse Stimulation pulses to non-thermally clear targeted cells while sparing adjacent non-cellular tissue, with revenue driven by system sales and related products such as electrodes.

The companys path to profitability depends on converting CellFX System adoption into meaningful system and related product revenue, because clinical and operating costs can outweigh early sales and drive large operating losses until that commercialization inflects.

Business quality (Weak): The disclosure provided emphasizes clinical feasibility outcomes (patient counts and a durability success rate) alongside very limited segment revenue detail, so investors should focus on whether clinical progress translates into sustained system and related product revenue.

Bull case

  • Durability outcome reported: The Durable Pulmonary Vein Isolation Success Rate (Three Months) is 94.2%.
  • Demonstrated clinical activity in feasibility studies: NanoClamp Atrial Fibrillation European Feasibility Patients Treated To Date is 44.

Bear case

  • Loss-making operating profile: For the latest period ending 2026-03-31, operating margin is -4775.6% and gross margin is 7.7%.
  • Revenue level shown as effectively zero in provided data: Provided revenue_b for the period is 0.0B, which implies limited offset to operating costs in the latest reported quarter.
Valuation — source: SEC EDGAR (first-party)
Price$47.91
Market Cap$3.42B
Price / Book34.34
Price / Sales2277.81
FCF Yield-2.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$350000.00
Net Margin-20794.6%
Financial Health — source: SEC EDGAR
Altman Z-Score132.67 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($28.93M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOPaul Arthur LaViolette
Employees75
CountryUS
IPO Date2016-05-18

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Merit Medical Systems, Inc. (MMSI)
  • Haemonetics Corporation (HAE)
  • ICU Medical, Inc. (ICUI)
  • iRhythm Technologies, Inc. (IRTC)
  • Heartflow, Inc. Common Stock (HTFL)
  • AtriCure, Inc. (ATRC)
  • UFP Technologies, Inc. (UFPT)
  • LeMaitre Vascular, Inc. (LMAT)
PLSE earnings history · PLSE institutional & insider holders · PLSE KPIs & operating metrics · PLSE financials · PLSE investor presentations & press releases · PLSE SEC filings · PLSE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.